1. 衛生福利部食品藥物管理署. 藥物許可證暨相關資料查詢作業. Available from: http://www.fda.gov.tw/MLMS/H0001.aspx (Accessed February 10, 2017)
2. 衛生福利部中央健康保險署 (2016) 全民健康保險藥物給付項目及支付 標準之藥品給付規定-105 年版. Avaulable from:
http://www.nhi.gov.tw/information/BBS_Detail.aspx?menu=9&menu_id=545
&bulletin_id=2255 (Accessed February 10, 2017)
3. CADTH: Rituximab for Non-Hodgkin's Lymphoma: A Review of the Clinical and Cost-Effectiveness and Guidelines; Published on January 11, 2010;
Available from:
https://www.cadth.ca/sites/default/files/pdf/L0147%20Rituximab%20for%20L ymphoma%20final.pdf ; Accessed on January 26, 2017.
4. PBAC: Rituximab; 1,400 mg/11.7 mL; solution for subcutaneous injection;
Mabthera® SC; Public summary document; Published on November, 2014;
Available from:
http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-11/fi les/rituximab-psd-11-2014.pdf ; Accessed on January 26, 2017.
5. NICE:Non-Hodgkin’s lymphoma: diagnosis and management; NICE Guidelines; Published July 20, 2016; Available from:
https://www.nice.org.uk/guidance/ng52/resources/nonhodgkins-lymphoma-dia gnosis-and-management-1837509936325 ; Accessed on January 26, 2017.
6. NICE: Non-Hodgkin's lymphoma: rituximab subcutaneous injection; Evidence summary ESNM46; Published on September 2014; Available from:
https://www.nice.org.uk/guidance/esnm46/resources/nonhodgkins-lymphoma-rituximab-subcutaneous-injection-1502680987649221 ; Accessed on January 26, 2017.
7. SMC: Rituximab 1400mg solution for Subcutaneous injection (Mabthera);
SMC No.(975/14); Published on July 7, 2014; Available from:
https://www.scottishmedicines.org.uk/files/advice/rituximab_subcutaneous_inj _Mabthera_FINAL_June_2014_for_website.pdf; Accessed on January 26, 2017.
8. Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. Journal of
clinical oncology : official journal of the American Society of Clinical
Oncology 2014; 32(17): 1782-1791.
9. Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of
subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. The Lancet Oncology 2014; 15(3): 343-352.
10. Davies A.J. MB, Mercadal S., Mihaylov G., Leppä S., Cotting D., Veenstra K., Zharkov A., Dixon M., Barrett M., Macdonald D. Longer term efficacy and safety of subcutaneous compared with intravenous rituximab: Updated results of the phase 3 SABRINA Study. Blood 2016; 128: 22.
11. Lugtenburg P. RA, Avivi I., Nagler A., Marolleau J.-P., Tani M., Berenschot H., Osborne S., Smith R., Pfreundschuh M. Subcutaneous versus intravenous rituximab in combination with chop for previously untreated diffuse large B-cell lymphoma: Efficacy and safety results from the phase iiib mabease study. Haematologica 2015; 100 SUPPL. 1: 178-179.
12. Athanasakis K, Papageorgiou L, Tsiantou V, et al. Rituximab sc vs rituximab iv for non-hodgkin's lymphomas (NHLS): An economic evaluation for the Greek healthcare system. Value in Health 2015; 18(7): A444.
13. Kulikov A, Rybchenko Y. Pharmacoeconomic study of the use of rituximab for subcutaneous administration in the treatment of follicular lymphoma. Value in
Health 2015; 18(7): A463.
14. Plommet N, Pau D, Tehard B. Economic evaluation and added value for stakeholders of switching from rituximab intravenous injection to rituximab subcutaneous injection in France. Value in Health 2015; 18(7): A664.
15. De Cock E, Kritikou P, Sandoval M, et al. Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries. PloS one 2016; 11(6): e0157957.
16. Ponzetti C, Canciani M, Farina M, Era S, Walzer S. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 italian hospitals based on a systematic survey. ClinicoEconomics and
Outcomes Research 2016; 8: 227-233.
17. Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: A time and motion study in the United Kingdom. Journal of Medical Economics 2014; 17(7): 459-468.
附錄
remission 或 complete remission)之病患，若在接受含 rituximab 誘導化學治療前有 下列情形之一者，得接受 rituximab 維持 治療，限用八劑，每三個月使用一劑，最 (platelet<100,000/mm
3
，或 Hb<10gm/dL，或 absolute neutrophil count<1500/mm
3
)。5.~7.(略)
附錄一 療效評估文獻搜尋紀錄
資料庫 查詢日期 篇數
篩 選 後 篇 數
Pubmed 2017.02.102
#1 non hodgkin lymphoma 98167
3
#2 rituximab 17058
#3 subcutaneous 130709
#4 #1 AND #2 AND #3 66
#5 "randomized "[All Fields] 6
EMBASE 2017.02.102
#1 'non hodgkin lymphoma'/exp OR
'non hodgkin lymphoma' 154881
3
#2 'rituximab'/exp OR rituximab OR
'mabthera'/exp OR mabthera 57540
#3 'subcutaneous' 217577
#4 #1 AND #2 AND #3 1,220
#5 "randomized control trial"[All
Fields] 47
Cochrane
Library 2017.02.102
Search all text: (Mabthera OR rituximab) AND non-Hodgkin lymphoma AND subcutaneous, limited to "randomized control trial"
7 0
附錄二 經濟評估文獻搜尋紀錄
資料庫 查詢日期 篇數 篩選後
篇數 Pubmed 2017.1.12 #1 non hodgkin lymphoma 97792 0
#2 (Mabthera) OR rituximab 16882
#3 subcutaneous 130225
#4 (((("Costs and Cost Analysis"[Mesh])) OR ((((cost-effectiveness analysis) OR cost-utility analysis) OR cost-benefit analysis) OR cost-minimization analysis))) OR economic evaluation
237578
#1 AND #2 AND #3 AND #4 1 EMBASE 2017.1.12 #1 'non hodgkin lymphoma'/exp OR 'non
hodgkin lymphoma'
151949 3
#2 'rituximab'/exp OR rituximab OR 'mabthera'/exp OR mabthera
56656
#3 'subcutaneous' 343177
#4 'economic evaluation'/exp OR 'economic evaluation' OR 'cost effectiveness
analysis'/exp OR 'cost effectiveness analysis' OR 'cost utility analysis'/exp OR 'cost utility analysis' OR 'cost benefit analysis'/exp OR 'cost benefit analysis' OR 'cost minimization analysis'/exp OR 'cost minimization analysis'
253740
#1 AND #2 AND #3 AND #4 47 Cochrane
Library
2017.1.12 Search all text: (Mabthera OR rituximab) AND non-Hodgkin lymphoma AND subcutaneous, limited to Economic Evaluations
0 0
CRD 2017.1.12 Mabthera OR rituximab 0 0 INAHTA 2017.1.12 Mabthera OR rituximab 0 0